LungLifeAI Logo

LungLife AI, with Collaborators from Mount Sinai and MD Anderson, to Present Clinical Data on Liquid Biopsy Test for Early Lung Cancer Detection

October 1, 2020

Thousand Oaks, CA – October 1, 2020 – LungLife AI, a leader in liquid biopsy technology for cancer diagnosis and management, announced today that clinical data from a research collaboration in early lung cancer detection will be presented at the International Association for the Study of Lung Cancer (IASLC) Hot Topic Meeting taking place on October 2nd and 3rd. The data highlight the Company’s progress in developing the LungLB® test which discriminates benign from malignant lesions in individuals with indeterminate lung nodules who are at-risk for lung cancer.

The study is being completed with collaborators from Mount Sinai Hospital in New York and MD Anderson Cancer Center in Houston, and demonstrates the potential of circulating tumor cells (CTC) for early lung cancer detection. LungLife AI is also presenting on the use of artificial intelligence in accurate CTC identification developed in partnership with Persistent Systems.

“Lung cancer spreads early and by using CTCs we are best positioned to find malignancy at the earliest possible stage,” says Paul Pagano, PhD, CEO at LungLife AI. “The majority of cancerous nodules in our study were diagnosed at Stage I, when the possibility for cure is greatest. We are delighted to have the opportunity to share results of our pilot study with scientists, physicians, and advocates.”

The following are the details for the two presentations:

Title:  Pilot study of a novel liquid biopsy test to discriminate benign vs malignant processes in subjects with indeterminate pulmonary nodules
Abstract Number: 034
Type: Oral Poster Presentation
Presenters: Joshua D Kuban1, Shahram Tahvilian2, Lara Baden2, Claudia I Henschke3, David F Yankelevitz3, Daniel Leventon2, Rebecca Reed2, Ashley Brown2, Allison Muldoon2, Michael J Donovan4, Paul C Pagano2

1.     Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX

2.     LungLife AI, Inc, Thousand Oaks, CA

3.     Department of Radiology, Icahn School of Medicine at Mount Sinai, New York, NY

4.     Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY 

Title:  Use of an artificial intelligence-derived algorithm for accurate FISH probe detection in a liquid biopsy test for lung cancer

Abstract Number:   039
Type: Poster Presentation
Presenters: Shahram Tahvilian1, Chinmay Savadikar2, Lara Baden1, Daniel Leventon1, Rebecca Reed1, Ashley Brown1, Michael J Donovan3, Bhushan Garware2, Paul C Pagano1

1.     LungLife AI, Inc, Thousand Oaks, CA

2.     Persistent Systems, Ltd, Pune, India

3.     Department of Pathology, Icahn School of Medicine at Mount Sinai, New York, NY. 

About LungLife AI, Inc.

LungLife AI is a cancer diagnostics company focused on transforming cancer diagnosis and management through artificial intelligence (AI) enabled molecular analysis of cancer biomarkers in blood.

LungLife AI is focused upon lung cancer diagnostic solutions recognizing the need to substantially improve patient outcomes. The company's testing methodology is designed to deliver actionable information to clinicians via a minimally invasive blood draw.

LungLife AI is based in Thousand Oaks, California. For more information, please visit

Recent News

Subscribe for Email Alerts

"*" indicates required fields

This field is for validation purposes and should be left unchanged.

LungLifeAI Logo
LungLife AI licensure/accreditation information posted here.
© 2023 LungLIfe AI, Inc.
All rights reserved. LiquidBiopsy is a trademark of LungLife AI, Inc.